Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
19 Mai 2023 - 10:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES
EXCHANGE ACT OF 1934
For the month of
May 2023
Commission File
Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its
Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
On May 19, 2023, CureVac N.V. (the “Company”) issued a
press release announcing certain developments to its ongoing patent litigation with Pfizer/BioNTech.
The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of the Company’s Chief Executive Officer contained in Exhibit 99.1 hereto) is hereby incorporated
by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
CUREVAC N.V. |
| |
|
|
| |
By: |
/s/ Alexander Zehnder |
| |
|
Chief Executive Officer |
Date: May 19, 2023
EXHIBIT INDEX
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
